Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum | |
8/28/2024 | $30.00 | Overweight | Wells Fargo | |
7/10/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup | |
3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS | |
2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan | |
1/4/2024 | $19.50 → $26.00 | In-line → Outperform | Evercore ISI | |
12/11/2023 | $95.00 → $72.00 | Buy → Neutral | Citigroup | |
12/11/2023 | $21.00 → $28.00 | Market Perform → Outperform | TD Cowen |
EcoVadis Rating validates Avantor's business sustainability commitments and performance RADNOR, Pa., Sept. 12, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today, for the second year in a row, that the Company has been awarded a Bronze Medal from EcoVadis, a global leader in business sustainability assessments. Avantor's latest score of 65, which was awarded in August 2024, places the Company in the top 17% of the more than 130,000 companies globally that have been rated by EcoVadis. The company's score is a 15-point improvement over its 20
QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.
QuidelOrtho Receives FDA 510(k) Clearance for its VITROS Syphilis Assay QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") has received U.S. Food and Drug Administration ("FDA") 510(k) clearance for its VITROS syphilis assay as part of its menu, strengthening QuidelOrtho's position as a leader in infectious disease testing. Using the automated VITROS systems, this assay is intended for the qualitative determination of total (IgG and IgM) antibodies to Treponema pallidum (TP)-specific antigens in human serum and plasma using the automated VITROS 3600, 5600 and XT 7600 systems. The presence of antibodies to TP-specific antigens, in conjunction with non-treponemal laboratory tests and cli
Craig Hallum upgraded QuidelOrtho from Hold to Buy and set a new price target of $57.00 from $40.00 previously
Wells Fargo initiated coverage of Avantor with a rating of Overweight and set a new price target of $30.00
Citigroup downgraded Avantor from Buy to Neutral and set a new price target of $23.00 from $30.00 previously
4 - QuidelOrtho Corp (0001906324) (Issuer)
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to be used for debt paydownRADNOR, Pa., Aug. 16, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively "Clinical Services"), to Audax Private Equity ("Audax") for a transaction value of approximately $650 million. "Today's announcement is an important step fo
— $100 million in annualized cost-savings initiatives will benefit second half 2024 and first half 2025 — — Strong progress on business review and refocusing R&D investments on core growth areas — Second quarter 2024 revenue was $637 million, as reported: Total recurring revenue1 grew 3% as reported and 5% in constant currency compared to the prior year period, excluding COVID-19 revenue and U.S. Donor Screening revenue YTD 2024 revenue was $1.35 billion, as reported: Total recurring revenue1 grew 6% as reported and 7% in constant currency compared to the prior year period, excluding COVID-19 revenue, a one-time third-party collaboration settlement and U.S. Donor Screening rev
Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0%Net income of $93 million; Adjusted EBITDA of $306 millionDiluted GAAP EPS of $0.14; adjusted EPS of $0.25Operating cash flow of $281 million; free cash flow of $235 millionRADNOR, Pa., July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024."Our teams delivered another solid quarter with sequential improvements to all key financial metrics. Improved mix from increased bioprocessing revenue together with t
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s
QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.
Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees
NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS
144 - QuidelOrtho Corp (0001906324) (Subject)
10-Q - QuidelOrtho Corp (0001906324) (Filer)
144 - Avantor, Inc. (0001722482) (Subject)